New Step Therapy Guidelines For MS Drugs; JAMA Research For Alzheimer’s

Beginning in April in 2014, BCBS of North Carolina will change its Multiple Sclerosis utilization management guidelines for all commercial members and for all types of formularies: Injectables Avonex and Extavia and orals Aubagio and Gilenya will be non-preferred while injectables Betaseron, Rebif and Copaxone and oral Tecfidera become preferred. To get a non preferred drug, a member or their doctor must first try and fail two different preferred medications (or, in the case of “orals”, at least try Tecfidera first)

Alzheimer’s induced agitation may be treatable by a high dose of antidepressants according to research in a recent JAMA

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s